|
|
|
Xeris Biopharma Holdings Inc (NASDAQ: XERS) |
|
|
|
| |
Xeris Biopharma Holdings Inc Outlook |
On March 6 2025 the Xeris Biopharma Holdings Inc provided following guidance
nnXeris Biopharma Holdings Inc. Reports Outstanding Fourth Quarter and Full-Year Performance for 2024, Alongside 2025 Financial Guidancenn
Xeris Biopharma Holdings Inc. (Nasdaq: XERS), a rapidly expanding biopharmaceutical firm focused on enhancing patient care through the development and marketing of pioneering therapeutic products, has released its financial results for the fourth quarter and the entire fiscal year ending December 31, 2024. The company also shared its financial outlook for 2025.
The year 2024 marked an exceptional period for Xeris, highlighted by record revenue exceeding $203 million, as noted by John Shannon, the company’s Chief Executive Officer. While Xeris has successfully demonstrated impressive growth and operational excellence in 2024, the specific financial targets or metrics for 2025 have not been disclosed in detail.
As Xeris positions itself for continued success in the coming year, stakeholders and investors are keenly awaiting further clarity on the expected financial performance for 2025. The company’s impressive traction in the biopharmaceutical market underscores its commitment to innovation and improving patient outcomes through its diverse range of therapies.
Xeris Biopharma remains focused on capitalizing on its recent achievements as it navigates the challenges and opportunities that 2025 presents.,
|
On January 10 2025 the Xeris Biopharma Holdings Inc provided following guidance
Xeris Biopharma Holdings Inc. has provided optimistic projections for its financial performance in 2024, signaling strong growth and robust fiscal health. The company estimates that its total revenue for the year will reach approximately $203 million, surpassing its prior guidance range of $198 million to $202 million. This upward adjustment illustrates Xeris' confidence in its product portfolio and market strategy.
In addition to revenue expectations, Xeris anticipates closing the year with a solid financial position, projecting to have over $71 million available in cash, cash equivalents, and short-term investments. This significant liquidity indicates a strong cash management strategy and the potential for investment in future initiatives. Furthermore, Xeris expects to achieve positive cash flow during the fourth quarter of 2024, reflecting effective operational efficiencies and revenue generation capabilities.
The company attributed its optimistic outlook to a recent record quarter, characterized by remarkable total revenue growth driven by robust demand for its products, including the Gvoke HypoPen. As Xeris continues to innovate and expand its market presence, these financial estimates reinforce its trajectory toward sustained success and shareholder value enhancement.
In summary, Xeris Biopharma Holdings Inc. is poised for a strong performance in 2024, with revenue projections exceeding previous guidance and a solid financial foundation as it moves into the new year.,
|
On May 9 2024 the Xeris Biopharma Holdings Inc provided following guidance
Xeris Biopharma Holdings Inc. reported its financial results for the first quarter of 2024, showing a 25% growth in total product revenue compared to the same period last year. This growth was achieved despite facing challenges such as an estimated $3 million negative impact on Gvoke revenue due to the Change Health.
The company remains committed to improving patient lives through the development and commercialization of innovative products across various therapies. Xeris Biopharma continues to focus on its growth-oriented approach to biopharmaceuticals.
In addition to the financial results, Xeris Biopharma also highlighted recent events in the first quarter of 2024. The company is dedicated to advancing its pipeline and expanding its presence in the biopharmaceutical industry.
Overall, Xeris Biopharma Holdings Inc. remains optimistic about its future prospects and is actively working towards achieving its goals of bringing innovative products to market and making a positive impact on patient lives.
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.
